DELRAY BEACH, Fla. -- (BUSINESS WIRE) -- VeriTeQ Corporation (“VeriTeQ” or “Company”) (OTC Markets: VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it will be featured at the RedChip Emerging Growth Showcase on Wednesday, January 22, 2014. VeriTeQ’s presentation will air at 12:00 pm ET at http://redchip.com/visibility/investor.asp?symbol=VTEQ&from=confpage31.
VeriTeQ’s Chairman and CEO Scott R. Silverman will discuss VeriTeQ’s FDA cleared Q Inside Safety Technology, which acts as an electronic serial number to identify implantable and reusable medical devices to help ensure the health, safety and wellness of patients. Q Inside Safety Technology gives physicians and patients access to a secure online database to retrieve device-specific data such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data. Q Inside Safety Technology also provides an extra level of protection to the patient in the event of a recall or other safety event. Silverman will also discuss the Company’s FDA cleared radiation dose measurement products, which help prevent radiation overdosing and under-dosing for patients undergoing radiation therapy treatment.
At the conclusion of his webcast presentation, Silverman will participate in a live question and answer session.
During the RedChip Emerging Growth Showcase, 25 small-cap company executives will provide detailed overviews of their businesses through video presentations and live Q&A sessions. Thousands of investors are expected to participate. No registration is required to view the event, which airs between 9:30 a.m. and 4 p.m. ET on January 22-23, 2014 at http://www.RedChip.com.
VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.
Statements in this press release about our future expectations constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, VeriTeQ’s ability to commercially launch its Q Inside Safety Technology in the EU in the first quarter of 2014; the Company’s ability to target the UDI sector and medical device manufacturers; VeriTeQ’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in VeriTeQ’s Forms 10-Q, filed on August 9, 2013 and November 14, 2013, and future filings with the Securities and Exchange Commission The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.